Epigenomics Finally Gains FDA Approval For Epi proColon Blood Test
Epigenomics has finally gained US FDA approval for its Epi proColon noninvasive colorectal cancer screening test, ending what has been a long, obstacle-filled journey for the German-US molecular diagnostics company.
You may also be interested in...
With the cost of treating colon cancer in the US projected to reach $20 billion annually by 2020, Exact Sciences hopes to improve colorectal cancer screening and survival rates with Cologuard, the first FDA-cleared noninvasive screening test that analyzes both DNA and blood biomarkers in stool.
DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.